ABPI Logo
  • Developing medicines
    • Responding to COVID-19
    • Clinical trials and research
    • Building a thriving environment for medicine discovery
    • UK-EU Future Relationship
    • Life Sciences Industrial Strategy
    • ABPI Medical Representatives Exam
  • Accessing medicines
    • How medicines are priced in the UK
    • Working with the NHS
    • Supply chain
    • Antimicrobial resistance (AMR)
    • Vaccines
    • What is the NICE Methods Review?
    • Rare diseases: Facing three challenges
  • Our ethics
    • ABPI Code of Practice
    • Disclosure UK
    • Appropriate prescribing
    • Patient & public involvement
  • Member representation
    • Events
    • Full membership
    • Working with our members​
    • ABPI Members List
    • Membership benefits
  • Who We Are
  • Media
  • Publications
  • Facts and Figures
  • Contact Us
MY ABPI LOGIN
 
  • The Association of the British Pharmaceutical Industry
  • Developing medicines
  • New medicines & data
  • Clinical trial transparency

Clinical trial transparency

Clinical trials are the cornerstone of the research and development process and it is through trials that pharmaceutical companies are able to demonstrate the safety and efficacy of new medicines.

The ABPI is committed to greater clinical trial transparency: we believe that clinical trial results should be posted in publicly accessible registries and databases and published in the scientific literature in a timely manner.

To help companies achieve this, the ABPI launched its clinical trial disclosure toolkit in the summer of 2013.

Clinical trial transparency has improved over five years of monitoring. Latest results show that for newly licensed medicines approved in 2014 the disclosure rate has reached 93% at 12 months (up from 71% in 2009) and 96% overall.

The ABPI Code of Practice refers to the IFPMA joint positions on the disclosure and publication of clinical trial information and results in that trials must be registered within 21 days of enrolling the first patient, and results must be published within one year of marketing authorisation or one year from completion for marketed products. This is in line with the IFPMA Code of Practice to support a global position on trials transparency.

The industry is also committed to enhancing public health through responsible sharing of clinical trial data consistent with the EFPIA/PhRMA principles of data sharing.

During 2017 pharmaceutical companies spent £370.9 million on research and development activities with healthcare professionals and healthcare organisations, the majority of this is for clinical trials.

Many companies have also collaborated to develop ClinicalStudyDataRequest.com and Vivli.org providing researchers with access to clinical trial data to further research that can help advance medical science or improve patient care.

ABPI clinical trial disclosure toolkit
Download the ABPI clinical trial disclosure toolkit here

New medicines & data

  • Medicines Manufacturing Industry Partnership
  • Manufacturing and quality
  • Research using animals
  • Clinical trial transparency

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2021
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Disclosure UK
  • Frequently Asked Questions
  • Careers
  • Schools
  • Acronym buster

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.